{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:26:32Z","timestamp":1761719192393,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-023-00777-8","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T10:03:07Z","timestamp":1676541787000},"page":"362-367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiac and renal AL amyloidosis controlled by autologous stem cell transplantation for 17\u00a0years accompanying late onset atrial fibrillation and complete atrioventricular block"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9266-9080","authenticated-orcid":false,"given":"Takashi","family":"Iijima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ikuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Yamanouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Suwabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Wake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Kono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Ubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"issue":"5","key":"777_CR1","first-page":"470","volume":"10","author":"YL Hwa","year":"2019","unstructured":"Hwa YL, et al. Immunoglobulin light-chain amyloidosis: clinical presentations and diagnostic approach. J Adv Pract Oncol. 2019;10(5):470\u201381.","journal-title":"J Adv Pract Oncol"},{"issue":"2","key":"777_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10741-014-9464-5","volume":"20","author":"M Grogan","year":"2015","unstructured":"Grogan M, Dispenzieri A. Natural history and therapy of AL cardiac amyloidosis. Heart Fail Rev. 2015;20(2):155\u201362.","journal-title":"Heart Fail Rev"},{"issue":"1","key":"777_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1272\/jnms.JNMS.2022_89-111","volume":"89","author":"T Ohara","year":"2022","unstructured":"Ohara T, et al. Long-term electrocardiographic follow-up of a patient with light-chain Cardiac amyloidosis. J Nippon Med Sch. 2022;89(1):119\u201325.","journal-title":"J Nippon Med Sch"},{"issue":"1","key":"777_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00392-019-01490-2","volume":"109","author":"F Escher","year":"2020","unstructured":"Escher F, et al. When and how do patients with cardiac amyloidosis die? Clin Res Cardiol. 2020;109(1):78\u201388.","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"777_CR5","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1038\/s41467-021-23880-9","volume":"12","author":"M Garofalo","year":"2021","unstructured":"Garofalo M, et al. Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity. Nat Commun. 2021;12(1):3532.","journal-title":"Nat Commun"},{"issue":"4","key":"777_CR6","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1080\/13506129.2016.1219715","volume":"23","author":"T Prokaeva","year":"2016","unstructured":"Prokaeva T, et al. Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio. Amyloid. 2016;23(4):214\u201320.","journal-title":"Amyloid"},{"issue":"11","key":"777_CR7","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa070484","volume":"357","author":"A Jaccard","year":"2007","unstructured":"Jaccard A, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357(11):1083\u201393.","journal-title":"N Engl J Med"},{"issue":"28","key":"777_CR8","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1200\/JCO.20.01285","volume":"38","author":"E Kastritis","year":"2020","unstructured":"Kastritis E, et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol. 2020;38(28):3252\u201360.","journal-title":"J Clin Oncol"},{"issue":"6","key":"777_CR9","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.clml.2019.11.005","volume":"20","author":"C Diaz-Pallares","year":"2020","unstructured":"Diaz-Pallares C, et al. Cyclophosphamide, bortezomib and dexamethasone (CyBorD) for the treatment of newly diagnosed AL amyloidosis: impact of response on survival outcomes. Clin Lymphoma Myeloma Leuk. 2020;20(6):394\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"777_CR10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014613","author":"AD Wechalekar","year":"2022","unstructured":"Wechalekar AD, Sanchorawala V. Daratumumab in amyloidosis. Blood. 2022. https:\/\/doi.org\/10.1182\/blood.2021014613. (Online ahead of print).","journal-title":"Blood"},{"issue":"2","key":"777_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-021-00428-0","volume":"11","author":"G Palladini","year":"2021","unstructured":"Palladini G, et al. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. Blood Cancer J. 2021;11(2):34.","journal-title":"Blood Cancer J"},{"issue":"2","key":"777_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1136\/heart.87.2.126","volume":"87","author":"K Miura","year":"2002","unstructured":"Miura K, et al. Epidemiology of idiopathic cardiomyopathy in Japan: results from a nationwide survey. Heart. 2002;87(2):126\u201330.","journal-title":"Heart"},{"issue":"5","key":"777_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/hrt.74.5.541","volume":"74","author":"S Dubrey","year":"1995","unstructured":"Dubrey S, et al. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J. 1995;74(5):541\u20134.","journal-title":"Br Heart J"},{"issue":"8","key":"777_CR14","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/europace\/euaa094","volume":"22","author":"EJ Kim","year":"2020","unstructured":"Kim EJ, et al. Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator. Europace. 2020;22(8):1216\u201323.","journal-title":"Europace"},{"issue":"10","key":"777_CR15","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1111\/jce.13046","volume":"27","author":"NY Tan","year":"2016","unstructured":"Tan NY, et al. Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol. 2016;27(10):1167\u201373.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"777_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ahj.2020.01.002","volume":"222","author":"RS Loungani","year":"2020","unstructured":"Loungani RS, et al. Outcomes following cardioversion for patients with cardiac amyloidosis and atrial fibrillation or atrial flutter. Am Heart J. 2020;222:26\u20139.","journal-title":"Am Heart J"},{"issue":"3","key":"777_CR17","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/ckj\/sfaa019","volume":"14","author":"JJ Hoelbeek","year":"2021","unstructured":"Hoelbeek JJ, et al. Renal amyloidosis: validation of a proposed histological scoring system in an independent cohort. Clin Kidney J. 2021;14(3):855\u201362.","journal-title":"Clin Kidney J"},{"issue":"8","key":"777_CR18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.46883\/ONC.2021.3508.0471","volume":"35","author":"I Vaxman","year":"2021","unstructured":"Vaxman I, Dispenzieri A. The role of autologous stem cell transplantation in amyloidosis. Oncology (Williston Park). 2021;35(8):471\u20138.","journal-title":"Oncology (Williston Park)"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-023-00777-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-023-00777-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-023-00777-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T10:11:58Z","timestamp":1698833518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-023-00777-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["777"],"URL":"https:\/\/doi.org\/10.1007\/s13730-023-00777-8","relation":{},"ISSN":["2192-4449"],"issn-type":[{"type":"electronic","value":"2192-4449"}],"subject":[],"published":{"date-parts":[[2023,2,16]]},"assertion":[{"value":"20 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The patient gave us his informed consent on HDM-ASCT. The study conforms to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}